BCAT1 and chronic myelogenous leukemia, BCR-ABL1 positive: Importantly from a therapeutic standpoint, knockdown of BCAT1 in a mouse model of CML improved survival, while use of the BCAT1 inhibitor gabapentin suppressed colony formation of human patient CML [18▪▪].